⌘K
OverviewStock screenerAnalyst actionsCalendar
MarketsInvestorsSign in
StockUnited StatesNasdaqGS

RXRX

Recursion Pharmaceuticals, Inc.

Healthcare · Biotechnology

3.215USD

-0.2250 (-6.54%)

DescriptionHistoricalFinancialsRelative ValueResearchNewsDiscussionOptionsPrice Chart ↗Fundamental Chart ↗
ProfileRatiosRevenue & EPS
Reading financial statements from SEC filings…
A first visit to a security takes a few seconds.
Fiscal Year End12/2025
Last Quarter End06/2026 Q2
Current/T12M(USD)
1)

Issue Data

Last PxUSD / 3.22
P/E—
Dvd Ind Yld—
P/B2.02
P/S33.6
Curr EV/T12M EBITDA-3.1
Mkt Cap (USD)1.8B
Curr EV (USD)1.5B
2)

Per Share Data

EPS T12M-1.07
DPS—
Bk Val Per Sh1.71
Rev/Sh0.10
Cash/Sh1.02
Curr Shares Out535.3M
FCF/Sh-0.66
3)

Cash Flow Analysis

P/CF-5.3
Curr P/FCF-5.2
CF/NI0.7
Dvd P/O0.0%
Cash Gen/Cash Reqd—
Csh Dvd Cov—
CFO/Sales-638.9%
Eff Interest Rate204.8%
4)

Growth Potential

Dil EPS 1Y Gr14.8%
Cap 1Y Gr9.3%
BPS 1Y Gr-33.0%
R&D To Sales719.2%
Retention Rate100.0%
Rev 1Y Gr26.9%
FCF 1Y Gr-1.5%
Assets 1Y Gr1.8%
5)

Profitability

EBITDA-0.5B
EBIT-0.5B
Operating Margin-991.7%
Pretax Margin-954.3%
Net Margin-945.9%
ROA-41.3%
ROE-56.6%
ROC-54.9%
Asset Turnover0.04
6)

Structure

Current Ratio5.03
Quick Ratio4.67
Debt/Assets5.5%
Debt/Com Eq7.3%
Net Debt/EBITDA1.03
Tot Debt/Capital6.8%
Gross Margin3.5%
EBIT/Int Exp-367.3

Returns and turnover use the AVERAGE balance over the year, not the closing snapshot. Growth rates compare the two most recent fiscal years.